ArticleResearch and practice in thrombosis and haemostasis2025
Heterozygous nonsense
Article in Research and practice in thrombosis and haemostasis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Megakaryocytes and platelets arise from hematopoietic stem and progenitor cells through a tightly regulated process involving various transcription factors, including erythroblast transformation-specific family member FLI1. Pathogenic variants in Objectives: In this study, we describe a patient with a de novo heterozygous nonsense mutation, Methods: Wild-type (WT) FLI1 and FLI1 p.Met100∗ were expressed in Meg01 cells. Bulk RNA sequencing, proteomics, and flow cytometry were performed to assess their functional consequences. Results: Western blot analysis confirmed truncated FLI1 p.Met100∗ protein expression in Meg01 cells. Gene set enrichment analysis revealed that WT FLI1 enhanced megakaryocytic phenotypes, while suppressing erythroid phenotypes, whereas FLI1 p.Met100∗ upregulated both. Flow cytometry confirmed that erythroid markers CD235a and KLF1 were downregulated by WT FLI1 but elevated by FLI1 p.Met100∗. Additionally, WT FLI1 promoted megakaryocyte maturation and adhesion, as evidenced by increased expression of the megakaryocyte marker CD61 and adhesion markers CD34 and CD44. Moreover, we demonstrated through immunoprecipitation that both WT FLI1 and FLI1 p.Met100∗ interact with shared cofactors. Conclusion: Collectively, our findings suggest that FLI1 p.Met100∗ impairs megakaryocyte maturation through a dominant-negative manner, potentially contributing to thrombocytopenia by promoting erythroid features at the expense of proper megakaryocytic development.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.